Efficacy and Tolerability of Entacapone as Adjunctive Therapy to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Deterioration in Daily Medical Practice: An Open, Multicenter Study

Entacapone is a potent, reversible and orally active inhibitor of catechol-O-methyltransferase. This open multicenter study evaluated the efficacy, safety and tolerability of entacapone as adjunct therapy to levodopa/dopa decarboxylase inhibitor (≧3 daily doses) in patients with idiopathic Parkinson...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European neurology 2001-01, Vol.45 (2), p.111-118
Hauptverfasser:	Durif, F., Devaux, I., Pere, J.-J., Delumeau, J.-C., Bourdeix, I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anticonvulsants. Antiepileptics. Antiparkinson agents Antiparkinson Agents - administration & dosage Antiparkinson Agents - adverse effects Biological and medical sciences Catechol O-Methyltransferase Inhibitors Catechols - administration & dosage Catechols - adverse effects Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dose-Response Relationship, Drug Drug Administration Schedule Drug Therapy, Combination Female Humans Levodopa - administration & dosage Levodopa - adverse effects Male Medical sciences Middle Aged Neurologic Examination Neurology Neuropharmacology Nitriles Original Paper Parkinson Disease - drug therapy Pharmacology. Drug treatments Prospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!